NASDAQ$MASI

Masimo Corp. · Q2 2022 earnings

Q2 2022 earnings · · Investor relations

Briefing

Reported strong performance in the second quarter, with revenue and earnings exceeding the high end of guidance, and raised financial guidance on a constant currency basis for fiscal year 2022.

Masimo reported consolidated revenue of $565.3 million, representing 85.3% growth compared to Q2 2021. Healthcare revenue was $357.0 million, a 17.0% increase, and non-healthcare revenue was $208.3 million. GAAP net income was $18.1 million, or $0.33 per diluted share, while non-GAAP net income was $74.8 million, or $1.35 per diluted share.

  • Consolidated revenue was $565 million.
  • Healthcare revenue was $357 million, representing 17% reported growth and 19% constant currency growth.
  • Non-healthcare revenue was $208 million.
  • Repurchased 3 million shares of Masimo common stock for $401 million.

Headline financials

Total Revenue

$565M

Previous: $305M+85.3%
EPS (adj)

$1.35

Previous: $0.94+43.6%
Capital Expenditures

-$30M

Previous: -$14.2M-110.6%
Free Cash Flow

-$11.9M

Previous: $36M-133.1%
Net Income

$18.1M

Previous: $50.2M-64.0%
Operating Income

$22.1M

Previous: $65.1M-66.1%
Gross Profit

$258M

Previous: $193M+33.8%
Cash & Equivalents

$218M

Previous: $576M-62.2%
Total Assets

$2.96B

No prior period
Stock-Based Comp

$17.3M

No prior period

Revenue & EPS history

Masimo · Revenue · Quarterly

$565M

Q2 2022+85.3%vs Q2 2021
Beat estimate in 9 of 14 quarters(64%)
ActualEstimate

Forward guidance

The Company provided the following estimates for its third-quarter and full-year 2022 guidance:

Tailwinds

  • Third-quarter 2022 consolidated revenue is expected to be between $515 million and $545 million.
  • Third-quarter 2022 healthcare revenue is expected to be between $320 million and $330 million.
  • Third-quarter 2022 non-healthcare revenue is expected to be between $195 million and $215 million.
  • Third-quarter 2022 consolidated earnings per diluted share are expected to be between $0.51 and $0.63 (GAAP) and $0.85 and $0.97 (Non-GAAP).
  • Full-year 2022 consolidated revenue is expected to be between $1,985 million and $2,045 million.

Headwinds

  • For our healthcare segment, our third-quarter 2022 and full-year 2022 revenue guidance includes year-over-year foreign currency headwinds of $10 million and $30 million, respectively.
  • Third-quarter 2022 GAAP net income between $27.7 million to $33.9 million
  • Third-quarter 2022 Non-GAAP net income between $46.2 million to $52.3 million
  • Full-year 2022 GAAP net income between $144.2 million to $157.2 million
  • Full-year 2022 Non-GAAP net income between $239.9 million to $252.9 million

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 19 quarterly earnings reports · overlaid with Q2 2022

Historical avgQ2 2022

-0.6%

Avg return

Earnings day

-0.1%

Avg return

5 days after

+1.6%

Avg return

30 days after

54%

35 / 65 earnings

Positive

+17.2%

Q2 2024

Best reaction

-35.8%

Q4 2021

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+0.2%+0.1%+0.4%
Q4 2025+0.1%+7.4%+0.6%
Q3 2025-4.8%-3.0%-4.9%
Q1 2025-6.5%+1.3%+6.5%
Q4 2024+12.3%+12.4%-3.5%
Q3 2024+13.7%+10.2%+14.9%
Q2 2024+17.2%+21.1%+9.0%
Q1 2024-13.0%-11.8%-9.6%
Q4 2023-1.5%-3.2%+12.4%
Q3 2023+2.5%+6.6%+30.5%
Q2 2023-4.1%-7.6%-11.8%
Q1 2023-7.0%-8.0%-16.1%
Q4 2022+4.1%+7.9%+5.6%
Q3 2022-12.1%+3.1%+10.1%
Q2 2022+2.1%-0.2%-0.4%
Q1 2022+7.5%+8.5%+19.8%
Q4 2021-35.8%-31.3%-29.9%
Q3 2021+1.4%-0.7%+0.1%
Q2 2021-0.6%+2.3%+3.8%
Q1 2021-6.9%-5.5%-12.4%
Q4 2020+0.5%+0.3%-9.6%
Q3 2020-5.1%-9.0%-0.3%
Q2 2020-7.2%-6.6%-6.7%
Q1 2020-0.6%+1.7%+9.3%
Q4 2019+0.2%-4.5%-14.5%
Q3 2019-1.5%-2.2%+4.7%
Q2 2019-2.8%-7.8%-3.2%
Q1 2019-1.5%+1.1%-2.9%
Q4 2018+1.3%+3.9%+5.5%
Q3 2018-2.2%-3.3%-4.5%
Q2 2018+8.9%+9.1%+18.6%
Q1 2018+4.3%+7.6%+10.2%
Q4 2017+2.2%-1.4%+2.7%
Q3 2017+1.3%-1.0%+2.3%
Q2 2017-10.3%-10.8%-11.5%
Q1 2017-14.2%-17.0%-12.5%
Q4 2016+5.7%+11.1%+21.9%
Q3 2016+5.5%+10.7%+12.3%
Q2 2016+9.3%+6.1%+14.0%
Q1 2016+7.7%
Q4 2015+5.7%
Q3 2015+4.0%
Q2 2015+6.2%
Q1 2015+1.0%
Q4 2014+8.0%
Q3 2014+7.0%
Q2 2014-11.2%
Q1 2014-9.1%
Q4 2013-4.2%
Q3 2013-9.2%
Q2 2013+5.5%
Q1 2013+7.5%
Q4 2012-0.3%
Q3 2012-1.1%
Q2 2012-6.2%
Q1 2012-6.6%
Q4 2009-3.8%
Q4 2011-3.8%
Q3 2011+1.1%
Q2 2011-8.4%
Q1 2011+4.0%
Q3 2010+0.0%
Q2 2010+1.1%
Q4 2010+1.1%
Q1 2010+2.9%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro